Payment overview · 2025
General Payments
$780.50
39 reported records · 12 companies
Healthcare provider profile · identity verified
Chamaine Renee Brooks-Locklear, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAURINBURG, NC · NPI 1619139029
Verified facts
What the public records show
CMS Open Payments records show Chamaine Renee Brooks-Locklear, M.D. received $780.50 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.39 | 25.2% | 11 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $190.58 | 24.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $105.30 | 13.5% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.04 | 10.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.05 | 7.3% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $43.72 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.13 | 2.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $18.59 | 2.4% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $18.51 | 2.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.50 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.48 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.21 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.50 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $190.58 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $120.47 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $110.11 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.04 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $75.92 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $59.32 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.05 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.05 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $45.98 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $43.72 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 142 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 129 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 187 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 356 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
129 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
187 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
83 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
356 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 660 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 465 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 111 |
| Lisinopril | Lisinopril | 423 | 122 |
| Ozempic | Semaglutide | 356 | 53 |
| Omeprazole | Omeprazole | 318 | 96 |
| Metformin Hcl | Metformin Hcl | 306 | 82 |
| Fluticasone Propionate | Fluticasone Propionate | 248 | 97 |
| Furosemide | Furosemide | 229 | 67 |
| Losartan Potassium | Losartan Potassium | 222 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 68 |
| Montelukast Sodium | Montelukast Sodium | 214 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 193 | 50 |
| Mounjaro | Tirzepatide | 187 | 29 |
| Trazodone Hcl | Trazodone Hcl | 186 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 169 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 49 |
| Naproxen | Naproxen | 155 | 54 |
| Temazepam | Temazepam | 151 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 146 | 33 |
| Jardiance | Empagliflozin | 142 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Simvastatin | Simvastatin | 130 | 34 |
| Linzess | Linaclotide | 129 | 42 |
| Pregabalin | Pregabalin | 129 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 121 | 33 |
| Meloxicam | Meloxicam | 119 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 32 |
| Ibuprofen | Ibuprofen | 113 | 45 |
| Eliquis | Apixaban | 109 | 25 |
| Buspirone Hcl | Buspirone Hcl | 107 | 21 |
| Potassium Chloride | Potassium Chloride | 105 | 30 |
| Tramadol Hcl | Tramadol Hcl | 99 | 21 |
| Alendronate Sodium | Alendronate Sodium | 95 | 26 |
| Carvedilol | Carvedilol | 93 | 25 |
| Allopurinol | Allopurinol | 92 | 23 |
| Ezetimibe | Ezetimibe | 91 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 29 |
| Trulicity | Dulaglutide | 83 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 81 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 17 |
| Mirtazapine | Mirtazapine | 78 | 22 |
| Donepezil Hcl | Donepezil Hcl | 75 | 23 |
| Famotidine | Famotidine | 75 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 21 |
| Lovastatin | Lovastatin | 65 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 17 |
| Glimepiride | Glimepiride | 63 | 21 |
| Sertraline Hcl | Sertraline Hcl | 62 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 19 |
| Atenolol | Atenolol | 55 | 13 |
| Meclizine Hcl | Meclizine Hcl | 55 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 18 |
| Glipizide | Glipizide | 52 | 16 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 25 |
| Spironolactone | Spironolactone | 47 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Colchicine | Colchicine | 40 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | 15 |
| Celecoxib | Celecoxib | 37 | suppressed |
| Prednisone | Prednisone | 37 | 31 |
| Primidone | Primidone | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Fluconazole | Fluconazole | 31 | 19 |
| Ondansetron Odt | Ondansetron | 30 | 19 |
| Rexulti | Brexpiprazole | 30 | 11 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Topiramate | Topiramate | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.50 · 39 records | Novo Nordisk Inc | AIRSUPRA, CAPLYTA, CREON, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), Heplisav-B, IBSRELA, JARDIANCE, LINZESS, MOUNJARO, Ozempic, REXULTI, Rybelsus, TZIELD, The Cologuard Plus Collection Kit, VIBERZI, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error